Steven John Green

Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom.

Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.

Founded in 2016, Amicus Therapeutics International Holding Ltd. is a British company that functions as an investment holding company. Part of Amicus Therapeutics, Inc., the company is based in Marlow, UK.

Founded in 2014, Silver Acquisition Co. Ltd. is a biotechnology research and British experimental development company. Part of Biogen, Inc., the company is based in Maidenhead, UK. The company's focus is on developing new biotechnology products through research and experimentation.

Part of Biogen, Inc., Convergence Pharmaceuticals Holdings Ltd. functions as an investment holding British company. The company is based in Maidenhead, UK.

Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom.

Founded in 2010, Old Convergence Pharmaceuticals Ltd. is a subsidiary of Biogen, Inc. that develops analgesics for the treatment of chronic pain. The company is based in Maidenhead, UK.